source
- Pathos AI partners with BMS and Tempus to use AI for Alzheimer’s drug developmentPathos AI announced two collaborations aimed at accelerating drug development for neurological disorders, including Alzheimer’s disease. The agreement with Bristol Myers Squibb gives the pharma co…
- Merck KGaA to acquire Silence Therapeutics for $1.1 billion, gaining Phase 3 PV siRNA assetMerck KGaA announced it will buy Silence Therapeutics for about $1.1 billion, giving the German group a foothold in hematology. Silence, a UK-based RNA specialist, develops short interfering RNA m…